Iceland· IS-EU/1/18/1267/001-006+013

Steglatro

A ertugliflozin product containing ertugliflozinum inn, registered in Iceland by Merck Sharp & Dohme B.V.*. The same ATC class is registered in 11 of our 19 countries.

ATC A10BK04

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedSteglatroATCA10BK04REGISTER NO.IS-EU/1/18/1267/001-0…PACKS LISTED0CHECKEDSeptember 29, 2026

Where it is registered

Ertugliflozin is registered in 11 of 19 countries.

Countries holding a registration under ATC A10BK04 (ertugliflozin), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 7 of them publish a price we can compare per daily dose

Ertugliflozin · ATC A10BK04

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ertugliflozin costs, country by country.

Normalised to the WHO defined daily dose (10 mg), the median price runs from $2.89 in Italy to $4.50 in Switzerland — a ×1.6 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Ertugliflozin · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$4.50
  • IT Italy$2.89
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Ertugliflozinum INN
Manufacturer
Merck Sharp & Dohme B.V.*
Country
Iceland (IS)
ATC code
A10BK04
ATC class
Ertugliflozin
Defined daily dose
10 mg, O
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

417 interactions on record for ertugliflozin.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ertugliflozin · interactions on record

417 records

  • 1 severe
  • 376 moderate
  • 40 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • PapaverineA03AD01moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ertugliflozin in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ertugliflozin products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Liechtenstein · Steglatro
  • Norway · Steglatro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/1d7210f3-2ef9-44b6-951c-a00abefcdbb4
GET /v1/drugs/1d7210f3-2ef9-44b6-951c-a00abefcdbb4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmuhúðuð tafla",
  "source": "lyfjastofnun",
  "atc_raw": "A10BK04",
  "marketed": false,
  "strength": "5 mg",
  "ma_number": "EU/1/18/1267/001-006+013",
  "substance": "Ertugliflozinum INN",
  "other_info": null,
  "legal_status": "(R) Lyfseðilsskylt",
  "ma_issued_serial": "43180"
}

See everything about ertugliflozin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.